AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Lynch Syndrome X-Talk of Enteral Mucosa With Immune System

Recruitingn/aAges 18 Years - anyAllSan Raffaele University
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Lynch syndrome (OMIM #120435) is the most common dominantly inherited colorectal cancer syndrome with an estimated prevalence of 1:270 individuals. It increases the lifetime risk of colorectal and endometrial cancer primarily, but it is associated with a high risk of other cancers (pancreas, stomach, ovarian, central nervous system, skin, among others). It is caused by a germline mutation in one of four DNA mismatch repair genes or a terminal deletion of the MSH2-adjacent gene EpCAM. Despite adherence to cancer surveillance programs, many patients still develop colorectal cancer and endometrial cancer. The Prospective Lynch Syndrome Database (PLSD) suggests that more frequent surveillance intervals do not significantly improve cancer risk reduction. The PLSD also revealed that the incidence of colorectal cancer in MLH1 and MSH2 carriers was even higher than previously expected, reaching

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria (for participants with Lynch syndrome): * Age โ‰ฅ18 years * All sexes eligible * Established diagnosis of Lynch syndrome performed as part of clinical practice, with a germline pathogenic/likely pathogenic variant in one of the following genes: MLH1, MSH2, MSH6, PMS2, and EpCAM * Subjects with Lynch syndrome undergoing surveillance gastrointestinal endoscopy and/or surgery according to clinical practice * Fertile patients (both males and females) are eligible * Lactating women are eligible Inclusion Criteria (for participants without Lynch syndrome): * Age โ‰ฅ18 years * All sexes eligible * Patients with sporadic colorectal lesions, including colorectal cancer and colorectal adenomas * Healthy controls without colorectal cancer or adenomas undergoing lower gastrointestinal endoscopy for abdominal pain * PREMM5 \< 2.5 \[PREMM5 is an online, free-to-use, clinical prediction algorithm that estimates the cumulative probability of an individual carrying a germline mutation in the mismatch repair genes responsible for Lynch syndrome\]. Exclusion Criteria (for participants with or without Lynch syndrome): * Age \< 18 years; * Diseases that are known to predispose to colorectal cancer (personal past or recent history of inflammatory bowel disease); * Patients unable/unwilling to provide consent; * Pregnancy
๐Ÿ’Š

What it tests

  • LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
๐Ÿ“

Where

5 sites
Beckman Research Institute at City of Hope
Monrovia, United States
Gastronterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Hospital
Milan, Italy
Dipartimento di Chirurgia Oncologica e Dipartimento di Oncologia Sperimentale Istituto Nazionale Tumori
Milan, Italy
Dipartimento di controllo qualitร  e rischio chimico biologico, AOOR Villa Sofia Cervello
Palermo, Italy
Chirurgia Generale, Azienda Ospedaliero Universitaria di Cagliari
Cagliari, Italy
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy